Investigational treatments and therapeutic targets in Becker muscular dystrophy

Bibliography

• Flanigan KM. Duchenne and becker muscular dystrophies. Neurol Clin 2014;32(3):671-88
   Google Scholar
• Romitti PA, Zhu Y, Puzhankara S, et al. Prevalence of duchenne and becker muscular dystrophies in the United States. Pediatrics 2015;135(3):513-21
   PubMed Web of Science ®Google Scholar
• Eagle M, Bourke J, Bullock R, et al. Managing duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17(6):470-5
   PubMed Web of Science ®Google Scholar
• Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 2012;31(2):121-5
   PubMedGoogle Scholar
• Leung DG, Wagner KR. Therapeutic advances in muscular dystrophy. Ann Neurol 2013;74(3):404-11
   Google Scholar
• Haas M, Vlcek V, Balabanov P, et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 2015;25(1):5-13
   PubMed Web of Science ®Google Scholar
• Finsterer J, Bittner RE, Grimm M. Cardiac involvement in Becker’s muscular dystrophy, necessitating heart transplantation, 6 years before apparent skeletal muscle involvement. Neuromuscul Disord 1999;9(8):598-600
   Google Scholar
• Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010;20(4):251-4
   PubMed Web of Science ®Google Scholar
• Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2(1):90-5
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Yagi M, Okizuka Y, et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet 2010;55(6):379-88
   PubMed Web of Science ®Google Scholar
• Dystrophin (DMD) sequence variations. Available from: http://www.dmd.nl/database.html [Accessed 30 March 2015]
   Google Scholar
• Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta 2014;1838(2):635-42
   PubMed Web of Science ®Google Scholar
• Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 2000;150(5):1209-14
   PubMed Web of Science ®Google Scholar
• Mazala DA, Grange RW, Chin ER. The role of proteases in excitation-contraction coupling failure in muscular dystrophy. Am J Physiol Cell Physiol 2015;308(1):C33-40
   Google Scholar
• Nigro V, Piluso G. Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects. Biochim Biophys Acta 2015;1852(4):585-93
   Google Scholar
• de Souza GT, Zanette Rde S, do Amaral DL, et al. Satellite cells: regenerative mechanisms and applicability in muscular dystrophy. Stem Cells Int 2015;2015:487467
   Google Scholar
• Ruegg UT. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 2013;26(5):577-84
   PubMed Web of Science ®Google Scholar
• Al-Zaidy S, Rodino-Klapac L, Mendell JR. Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol 2014;51(5):607-18
   PubMed Web of Science ®Google Scholar
• Kornegay JN, Spurney CF, Nghiem PP, et al. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J 2014;55(1):119-49
   PubMed Web of Science ®Google Scholar
• Jarmin S, Kymalainen H, Popplewell L, Dickson G. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 2014;14(2):209-30
   PubMed Web of Science ®Google Scholar
• Bertoni C. Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol 2014;5:148
   Google Scholar
• Tidball JG, Bertoni C. Purloined mechanisms of bacterial immunity can cure muscular dystrophy. Cell Metab 2014;20(6):927-9
   Google Scholar
• Li HL, Fujimoto N, Sasakawa N, et al. Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 2015;4(1):143-54
   PubMed Web of Science ®Google Scholar
• Ousterout DG, Kabadi AM, Thakore PI, et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015;6:6244
   PubMed Web of Science ®Google Scholar
• Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther 2010;18(2):386-93
   Google Scholar
• Tedesco FS. Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes. Chromosome Res 2015;23(1):135-41
   Google Scholar
• Matsuo M. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev 1996;18(3):167-72
   Google Scholar
• Hoffman E. A rebirth for drisapersen in Duchenne muscular dystrophy? Lancet Neurol 2014;13(10):963-5
   PubMed Web of Science ®Google Scholar
• Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013;74(5):637-47
   PubMed Web of Science ®Google Scholar
• Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014;13(10):987-96
   PubMed Web of Science ®Google Scholar
• Takeshima Y, Yagi M, Matsuo M. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing. Methods Mol Biol 2012;867131-41
   Google Scholar
• Goyenvalle A, Griffith G, Babbs A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 2015;21(3):270-5
   PubMed Web of Science ®Google Scholar
• Howard MT, Anderson CB, Fass U, et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004;55(3):422-6
   PubMed Web of Science ®Google Scholar
• Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 2013;64:407-25
   PubMed Web of Science ®Google Scholar
• Malik V, Rodino-Klapac LR, Viollet L, et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 2010;67(6):771-80
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ [Accessed 30 March 2015]
   Google Scholar
• Shiozuka M, Matsuda R. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy]. Brain Nerve 2011;63(11):1253-60
   PubMedGoogle Scholar
• Wein N, Vulin A, Falzarano MS, et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med 2014;20(9):992-1000
   PubMed Web of Science ®Google Scholar
• Lamande SR, North KN. Activating internal ribosome entry to treat Duchenne muscular dystrophy. Nat Med 2014;20(9):987-8
   Google Scholar
• Tinsley JM, Fairclough RJ, Storer R, et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 2011;6(5):e19189
   PubMed Web of Science ®Google Scholar
• Tinsley J, Robinson N, Davies KE. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol 2015;55(6):698-707
   PubMed Web of Science ®Google Scholar
• Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12(10):917-25
   Google Scholar
• Moxley RT III, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25(9):1116-29
   PubMed Web of Science ®Google Scholar
• Judge DP, Kass DA, Thompson WR, Wagner KR. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am J Cardiovasc Drugs 2011;11(5):287-94
   PubMed Web of Science ®Google Scholar
• Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015;14(2):153-61
   Google Scholar
• Goemans N, Buyse G. Current treatment and management of dystrophinopathies. Curr Treat Options Neurol 2014;16(5):287
   Google Scholar
• Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain 2008;131(Pt 11):2824-31
   Google Scholar
• Rimessi P, Fabris M, Bovolenta M, et al. Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudoexon responsible for x-linked dilated cardiomyopathy. Hum Gene Ther 2010;21(9):1137-46
   Google Scholar
• Fletcher S, Meloni PL, Johnsen RD, et al. Antisense suppression of donor splice site mutations in the dystrophin gene transcript. Mol Genet Genomic Med 2013;1(3):162-73
   Google Scholar
• Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461(7262):402-6
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kataoka N, Miyauchi K, et al. Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc Natl Acad Sci U S A 2015;112(9):2764-9
   Google Scholar
• Flanigan KM, Dunn DM, von Niederhausern A, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat 2011;32(3):299-308
   PubMed Web of Science ®Google Scholar
• Shiga N, Takeshima Y, Sakamoto H, et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest 1997;100(9):2204-10
   Google Scholar
• Nishida A, Kataoka N, Takeshima Y, et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011;2:308
   PubMed Web of Science ®Google Scholar
• Sharma A, Paranjape A, Sane H, et al. Cellular Transplantation Alters the Disease Progression in Becker’s Muscular Dystrophy. Case Rep Transplant 2013;2013:909328
   Google Scholar
• Sharma A, Sane H, Badhe P, et al. A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. Cell Transplant 2013;22(Suppl 1):S127-38
   Google Scholar
• Thomas GD. Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front Physiol 2013;4:381
   Google Scholar
• Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012;4(162):162ra55
   Web of Science ®Google Scholar
• Witting N, Kruuse C, Nyhuus B, et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. Ann Neurol 2014;76(4):550-7
   Google Scholar
• Leung DG, Herzka DA, Thompson WR, et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol 2014;76(4):541-9
   PubMed Web of Science ®Google Scholar
• Nelson MD, Rader F, Tang X, et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014;82(23):2085-91
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2015;23(1):192-201
   PubMed Web of Science ®Google Scholar
• Nakae Y, Dorchies OM, Stoward PJ, et al. Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea. Histochem Cell Biol 2012;137(6):811-27
   PubMed Web of Science ®Google Scholar
• Angelini C, Fanin M, Pegoraro E, et al. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord 1994;4(4):349-58
   Google Scholar
• Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134(Pt 12):3547-59
   Google Scholar
• Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993;240(2):98-104
   Google Scholar
• Nicolas A, Raguenes-Nicol C, Ben Yaou R, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet 2015;24(5):1267-79
   Google Scholar
• Heald A, Anderson LVB, Bushby KMD, Shaw PJ. Becker muscular dystrophy with onset after 60 years. Neurology 1994;44(12):2388-90
   PubMed Web of Science ®Google Scholar
• England SB, Nicholson LVB, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990;343(6254):180-2
   PubMed Web of Science ®Google Scholar
• Palmucci L, Doriguzzi C, Mongini T, et al. Unusual expression and very mild course of Xp21 muscular dystrophy (Becker type) in a 60-year-old man with 26 percent deletion of the dystrophin gene. Neurology 1994;44(3 Pt 1):541-3
   Web of Science ®Google Scholar
• Bosone I, Bortolotto S, Mongini T, et al. Late onset and very mild course of Xp21 Becker type muscular dystrophy. Clin Neuropathol 2001;20(5):196-9
   Google Scholar
• Finsterer J, Stollberger C. Spontaneous left ventricular hypertrabeculation in dystrophin duplication based Becker’s muscular dystrophy. Herz 2001;26(7):477-81
   PubMed Web of Science ®Google Scholar
• Ferreiro V, Giliberto F, Muniz GM, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009;39(2):239-43
   PubMed Web of Science ®Google Scholar
• Flanigan KM, Dunn DM, von Niederhausern A, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009;30(12):1657-66
   PubMed Web of Science ®Google Scholar
• Momma K, Noguchi S, Malicdan MC, et al. Rimmed vacuoles in Becker muscular dystrophy have similar features with inclusion myopathies. PLoS ONE 2012;7(12):e52002
   Google Scholar
• van den Bergen JC, Wokke BH, Janson AA, et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry 2014;85(7):747-53
   Google Scholar
• Findlay AR, Wein N, Kaminoh Y, et al. Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45. Ann Neurol 2015;77(4):668-74
   PubMed Web of Science ®Google Scholar
• Moat SJ, Bradley DM, Salmon R, et al. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 2013;21(10):1049-53
   PubMed Web of Science ®Google Scholar
• Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 2015;385:1748-57
   PubMed Web of Science ®Google Scholar
• Mercuri E, Muntoni F. Efficacy of idebenone in Duchenne muscular dystrophy. Lancet 2015;385(9979):1704-6
   Google Scholar